Promacta / Revolade 25 mg Alternative – Elopag (Eltrombopag) 25 mg Tablet | Everest Pharmaceuticals

Product Overview

Elopag 25 mg Tablet by Everest Pharmaceuticals Ltd., Bangladesh contains Eltrombopag. It is listed here as a same-ingredient branded option for people researching Promacta / Revolade, a reference brand associated with Novartis. Elopag and Promacta / Revolade must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 25 mg strength.

Elopag vs. Promacta / Revolade – Originator / Reference Brand Comparison

Promacta / Revolade is a widely recognized reference brand for Eltrombopag associated with Novartis. Elopag is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Elopag is manufactured by Novartis, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.

Composition and Active Ingredient

Active ingredient: Eltrombopag
Strength: 25 mg
Dosage form: Tablet
Pharmacological class: thrombopoietin receptor agonist
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.

Therapeutic Uses and Indications

Eltrombopag is used in selected immune thrombocytopenia and aplastic anemia settings. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.

Mechanism of Action – How Eltrombopag Works

Eltrombopag is a thrombopoietin receptor agonist. In general, it stimulates platelet production through thrombopoietin receptors. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.

Dosage and Administration

The product contains 25 mg per tablet; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.

Contraindications

Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.

Warnings and Precautions

Important precautions for Eltrombopag include: liver injury, thrombosis and interactions with calcium or mineral-containing products. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.

Possible Side Effects

The adverse-effect profile of Eltrombopag varies by indication and combination regimen. Relevant potential adverse effects and serious risks include liver injury, thrombosis and interactions with calcium or mineral-containing products. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.

Drug Interactions

Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Eltrombopag. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.

Pregnancy, Fertility and Breastfeeding

Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Eltrombopag without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.

Storage and Handling

Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.

Why Is Elopag Listed as an Alternative to Promacta / Revolade?

This listing helps customers identify an Everest Pharmaceuticals product containing Eltrombopag while researching Promacta / Revolade. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.

Manufacturer Information

Listed brand: Elopag
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Promacta / Revolade
Reference company: Novartis
Generic ingredient: Eltrombopag
Strength: 25 mg
Dosage form: Tablet
Therapeutic class: thrombopoietin receptor agonist

Frequently Asked Questions

What is Elopag 25 mg?

It is an Everest Pharmaceuticals tablet containing Eltrombopag 25 mg.

Is Elopag the same as Promacta / Revolade?

They are presented as brands associated with Eltrombopag, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.

What is Eltrombopag used for?

Eltrombopag is used in selected immune thrombocytopenia and aplastic anemia settings, subject to the applicable label and clinical assessment.

How does Eltrombopag work?

It stimulates platelet production through thrombopoietin receptors.

Can I switch strengths or brands myself?

No. A licensed prescriber or pharmacist must assess any substitution.

Is a prescription needed?

Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.

Important Medical Disclaimer

This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.